Focused on ALK+ Non-small cell lung cancer (NSCLC), Xcovery, a biopharmaceutical company working to improve the lives of patients with cancer. Xcovery is currently enrolling patients with prior crizotinib and/or alectinib for its Phase 2 clinical trial. In addition, Xcovery is enrolling patients and sites for its Phase 3 clinical trial in tyrosine kinase inhibitor naïve ALK+ NSCLC patients.